查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1870858

厭食症市場按治療方法、療法、最終用戶和年齡層別分類 - 全球預測 2025-2032 年

Anorexia Nervosa Market by Treatment Type, Therapy Type, End User, Age Group - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，神經性厭食症市場將成長至 2.986 億美元，複合年成長率為 13.70%。

主要市場統計數據
基準年 2024 1.0687億美元
預計年份：2025年 1.2183億美元
預測年份：2032年 2.986億美元
複合年成長率 (%) 13.70%

針對神經性厭食症的綜合框架強調了整合的臨床要務、符合發展階段的應對措施以及不斷發展的服務管道，旨在改善患者的治療效果。

神經性厭食症是行為健康領域最頑固、最複雜的挑戰之一，它不僅涉及嚴重的營養障礙，還伴隨著根深蒂固的心理模式，需要協調一致的臨床應對。近年來，臨床實踐和政策的進步提高了人們對該疾病長期致殘性的認知，並強調了在急性期、過渡時期和社區護理的各個階段建立整合管道的必要性。過去十年，臨床醫生和醫療系統日益重視早期發現、家庭參與式照護模式以及銜接醫療穩定性、營養復健和針對性心理治療的多學科干預措施。

技術應用、早期療育策略以及支付方主導的整合正在重新定義臨床環境中的護理路徑和治療強度。

隨著臨床實務、技術和政策的交會融合，厭食症的治療模式正在發生顯著變化，治療路徑和病患體驗也隨之重塑。遠端醫療的擴展已從疫情期間的權宜之計轉變為一種永續的方法，它與面對面諮詢相輔相成，使患者能夠跨越地域限制獲得持續的醫療服務，並改善服務不足地區的就醫途徑。同時，數位化評估工具和遠端監測平台正在幫助臨床醫生追蹤患者就診間生理參數和症狀的變化，從而實現更及時的干涉，並在治療的關鍵早期階段降低風險。

不斷變化的關稅政策對供應鏈、實驗室物流和籌資策略的影響，進而影響厭食症專科護理的連續性和成本。

關稅政策和不斷變化的跨境貿易動態對供應鏈、藥品進口以及醫療服務中使用的專用醫療設備的成本結構都產生了下游影響。對於依賴進口營養品、醫療監測設備和特殊配方的醫療機構而言，關稅波動正迫使其調整籌資策略和庫存管理，從而重新評估採購結構和庫存緩衝，以確保醫療服務的連續性。醫療系統和獨立醫療機構正在透過擴大供應商選擇範圍、盡可能增加在地採購以及協商更靈活的合約條款來應對關稅波動帶來的風險。

透過整合治療環境、治療方法、提供者類型和發展階段，落實差異化照護路徑並取得更佳療效。

按治療類型細分護理連續體，揭示了不同的資源和臨床強度特徵，因此需要採取差異化的營運應對措施。日間護理計畫、住院護理和住宿護理各自需要特定的人員編制模式、臨床管治和醫療監測通訊協定。患者在這些護理等級之間的過渡受益於標準化的交接流程和共用的療效評估指標，從而最大限度地減少臨床挫折。同時，不同的治療方法也影響臨床重點和訓練需求。營養諮詢為體重恢復和飲食支持奠定了基礎；藥物治療（包括非典型抗精神病藥物和選擇性血清素再回收抑制劑的選擇性使用）針對合併症狀；心理治療（透過認知行為療法、家庭療法和人際關係療法）則著重解決疾病的認知和關係因素。

從區域觀點探討影響飲食障礙治療服務取得、服務設計和創新的臨床基礎設施、文化動態和政策框架。

區域動態影響著從臨床文化到法規結構和報銷機制的方方面面，導致不同地區的服務可及性和照護模式存在差異。在美洲，強大的研究基礎、集中化的卓越臨床中心以及不斷發展的支付模式正在推動整合式醫療管道的創新，但農村和都市區仍然存在醫療資源獲取方面的差距。該地區的醫療服務提供者正擴大採用遠端醫療和協作式護理模式，將專業知識擴展到社區，而支付方則在探索以以金額為準的合約模式，以獎勵持續康復和減少醫療併發症。

評估透過整合系統、專科診所、遠端醫療平台和臨床開發人員提供跨專業護理的組織格局

參與神經性厭食症治療的組織生態系統包括綜合醫療系統、專業行為健康診所、遠端醫療平台以及提供輔助工具用於監測和症狀管理的製藥和醫療設備開發商。醫療系統和醫院是醫療穩定和複雜合併症管理的中心，通常與專科診所合作，以確保心理社會照護的連續性。專科診所通常匯集多學科護理團隊的專業知識，包括營養師、心理學家、精神科醫生和護士，以開發可在不同服務領域複製的治療方案。

醫療保健經營團隊的策略重點：擴大臨床照護、整合遠端醫療、加強採購和建立以結果為導向的臨床管治。

致力於加強神經性厭食症服務的領導者應優先考慮擴大臨床服務能力，同時確保服務品質和連續性。首先，應投資於人力資源開發，重點為包括醫生、營養師、心理健康臨床醫生和護理協調員在內的多學科團隊提供基於能力的培訓，並在各級引入標準化的交接流程，以降低不同層級護理之間的過渡風險。其次，應策略性地整合遠端醫療，以擴大專科護理的覆蓋範圍並實現分級診療模式。將高強度的線下治療項目與線上追蹤和看護者指導相結合，以維持治療效果並降低再入院率。

一種透明、多方面的方法，結合文獻綜述、專家訪談和營運數據，以臨床證據為基礎得出可操作的見解。

本研究綜合運用了系統性文獻回顧、專家訪談和多學科證據評估，以確保提供全面且具有臨床基礎的觀點。同行評審的臨床研究、實踐指南和共識聲明為治療和干涉建議提供了臨床框架，而對臨床醫生、計畫主管和支付方的定性訪談則提供了營運背景，並深入分析了就醫障礙和報銷動態。來自服務提供者和技術供應商的數據則為醫療服務創新提供了見解，尤其關注遠端醫療和遠端監測的作用。

整合臨床和營運重點，透過綜合性、發展敏感度和適應性發展階段。

神經性厭食症的治療正處於一個轉捩點。儘管臨床進展、服務模式創新和政策轉變為改善治療效果創造了機遇，但也需要整個治療鏈中各機構採取策略性應對措施。需求顯而易見：優先考慮早期介入和家庭參與式干涉，整合醫療和社會心理護理，並利用遠端醫療和數位監測來提高服務的可及性和連續性。同時，營運韌性，尤其是在採購和供應鏈規劃方面，對於防止可能損害復原的服務中斷至關重要。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 人工智慧驅動的數位篩檢工具問世，用於早期檢測神經性厭食症
  • 擴大遠端保健平台，提供遠距飲食障礙治療和支持
  • 將基因和腸道菌叢分析整合到個人化營養補充品中
  • 虛擬實境暴露療法在改善患者扭曲的身體意象方面正得到越來越廣泛的應用。
  • 增加對含有認知行為療法模組的行動心理健康應用程式的投資，以治療厭食症
  • 透過加強保險公司和專科診所之間的合作，改善患者獲得治療的機會。
  • 利用社交媒體建立由同儕主導的線上復健社區，促進病人參與

第6章美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 厭食症市場（依治療方法）

  • 日間治療計劃
  • 住院治療
  • 住院治療

9. 厭食症治療市場

  • 營養諮詢
  • 藥物治療
    • 非典型抗精神病藥物
    • 選擇性血清素再回收抑制劑（SSRIs）
  • 心理治療
    • 認知行為療法
    • 家庭治療
    • 人際關係療法

第10章 以最終用戶分類的神經性厭食症市場

  • 醫院
  • 專科診所
  • 遠端醫療提供者

第11章 依年齡層別分類的神經性厭食症市場

  • 青春期
  • 成人
  • 兒童

第12章 各地區的神經性厭食症市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 神經性厭食症市場（依群體分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 各國神經性厭食症市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Acadia Healthcare Company, Inc.
    • Universal Health Services, Inc.
    • Rogers Behavioral Health
    • Eating Recovery Center, LLC
    • Monte Nido & Affiliates, LLC
    • Walden Behavioral Care, Inc.
    • The Renfrew Center, Inc.
    • Priory Group Ltd
Product Code: MRR-1A1A064C0422

The Anorexia Nervosa Market is projected to grow by USD 298.60 million at a CAGR of 13.70% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 106.87 million
Estimated Year [2025] USD 121.83 million
Forecast Year [2032] USD 298.60 million
CAGR (%) 13.70%

A comprehensive framing of anorexia nervosa that highlights integrated clinical imperatives, developmental tailoring, and the evolving delivery pathways for improved patient outcomes

Anorexia nervosa presents one of the most persistent and complex challenges in behavioral health, combining severe nutritional compromise with entrenched psychological patterns that demand coordinated clinical responses. Recent clinical practice and policy developments have heightened awareness of the condition's long-term morbidity and the need for integrated pathways across acute, intermediate, and community settings. Over the past decade clinicians and health systems have increasingly prioritized earlier identification, family-inclusive models of care, and multidisciplinary interventions that bridge medical stabilization, nutritional rehabilitation, and targeted psychotherapy.

This executive summary synthesizes clinically relevant evidence and service-delivery trends to support decision-makers in healthcare delivery, policy, and life sciences. It focuses on the modalities that shape care access and quality, including treatment settings, therapy approaches, provider types, and age-specific adaptations. While clinical nuance varies by patient presentation, common themes emerge: the imperative of tailoring interventions to developmental stage, the critical role of coordinated medical oversight during weight restoration, and the centrality of psychosocial therapies to sustain recovery. In addition, evolving care delivery mechanisms and payer interactions are influencing how services are organized and reimbursed, with implications for clinical outcomes and operational sustainability.

Taken together, these considerations underscore the need for strategic investments in workforce training, care integration, and evidence-based program design to meet rising clinical complexity and evolving patient expectations.

How technological adoption, earlier intervention strategies, and payer-driven integration are redefining care pathways and treatment intensity across clinical settings

The landscape of anorexia nervosa care has shifted markedly as clinical practice, technology, and policy intersect to reshape treatment trajectories and patient experience. Telehealth expansion has moved from a pandemic-era stopgap to a durable modality that augments in-person care, enabling continuity for patients across distances and improving access for those in underserved regions. Concurrently, digital assessment tools and remote monitoring platforms support clinicians in tracking physiological parameters and symptom trajectories between visits, which in turn informs more timely interventions and reduces risk during the critical early phases of treatment.

At the same time, clinical paradigms have evolved to favor earlier engagement and family-inclusive strategies, driven by evidence supporting improved outcomes with developmentally attuned interventions. Psychotherapeutic modalities such as cognitive behavioral therapy and family-based approaches have seen refinements in protocols and wider adoption across settings, while nutritional counseling has been integrated more closely with medical oversight to accelerate stabilization without compromising psychological work. Pharmacotherapy continues to play a secondary yet important role, primarily for co-occurring psychiatric symptoms and selective indications; the use of atypical antipsychotics and selective serotonin reuptake inhibitors remains targeted and adjunctive rather than primary.

These transformative shifts have been reinforced by payer and policy adjustments that emphasize stepped-care pathways, quality metrics tied to clinical outcomes, and incentives for integrated behavioral health models. As a result, providers and system leaders are redesigning care pathways to balance intensity, accessibility, and quality across day treatment programs, inpatient hospitalization, and residential treatment modalities.

Impacts of evolving tariff policies on supply chains, clinical trials logistics, and procurement strategies that influence continuity and cost of specialized anorexia nervosa care

Changes in tariff policy and cross-border trade dynamics have downstream effects on supply chains, pharmaceutical imports, and the cost structure of specialized medical equipment used in care delivery. For providers reliant on imported nutritional products, medical monitoring devices, or specialty formulations, shifts in tariffs alter procurement strategies and inventory management, prompting organizations to reassess sourcing arrangements and inventory buffers to maintain continuity of care. Health systems and independent providers are responding by broadening supplier panels, increasing local procurement where feasible, and negotiating more flexible contracting terms to mitigate exposure to tariff volatility.

Pharmaceutical development and clinical trials can also be affected indirectly through changes in the cost base for importing investigational supplies and equipment. Clinical program managers and sponsors are integrating tariff considerations into trial budgeting and logistics planning to avoid disruptions to dosing regimens or monitoring schedules. In tandem, international collaborations for research and training may require recalibration of resource flows and event planning when cross-border expenses shift.

Importantly, shifts in trade policy compel payer and provider procurement teams to adopt scenario planning that anticipates periods of price instability, with an emphasis on maintaining clinical quality and uninterrupted access to essential supplies. By embedding tariff sensitivity into supply-chain governance and contracting, organizations can preserve treatment continuity and protect vulnerable patients from gaps in care that could adversely affect clinical recovery trajectories.

Segmentation-driven insights that align treatment setting, therapeutic modality, provider type, and developmental stage to operationalize differentiated care pathways for better outcomes

Disaggregating the care continuum by treatment type reveals distinct resource and clinical intensity profiles that require differentiated operational responses. Day Treatment Program, Inpatient Hospitalization, and Residential Treatment each demand specific staffing models, clinical governance, and medical monitoring protocols; transitioning patients between these levels of care benefits from standardized handoffs and shared outcome metrics to minimize clinical regression. By contrast, therapy modality distinctions shape the clinical focus and training needs: Nutritional Counseling serves as the backbone of weight restoration and meal support, Pharmacotherapy-used selectively and inclusive of Atypical Antipsychotics and Selective Serotonin Reuptake Inhibitors-targets comorbid symptoms, and Psychotherapy-implemented through Cognitive Behavioral Therapy, Family Based Therapy, and Interpersonal Therapy-addresses the cognitive and relational drivers of illness.

End-user segmentation highlights where investment and innovation can have immediate operational impact. Hospitals deliver integrated medical stabilization and psychiatric liaison services; Specialized Clinics concentrate on multidisciplinary eating-disorder expertise and programmatic continuity; and Telehealth Providers extend reach and continuity through virtual platforms that support outpatient follow-up and caregiver coaching. Each end-user type faces unique challenges in workforce development, reimbursement navigation, and quality assurance.

Age-based considerations are equally critical: adolescents often require family-centered interventions and coordination with schools, adults may present with longer illness duration and comorbidities necessitating coordinated medical and psychiatric management, and children call for developmentally calibrated approaches that balance parental involvement with age-appropriate engagement. By weaving together treatment type, therapy approach, provider setting, and age group considerations, stakeholders can design care pathways that align clinical intensity with patient needs and system capacity.

A regional perspective on how clinical infrastructure, cultural dynamics, and policy frameworks shape access, service design, and innovation in eating-disorder care

Regional dynamics shape everything from clinical culture to regulatory frameworks and reimbursement practices, driving variation in service availability and care models across geographies. In the Americas, robust research infrastructure, concentrated centers of clinical excellence, and evolving payer models have driven innovations in integrated care pathways, while persistent access gaps remain in rural and underserved urban communities. Providers in this region increasingly adopt telehealth and collaborative care arrangements to extend specialty expertise into community settings, and payers are exploring value-based arrangements that reward sustained recovery and reduced medical complications.

Across Europe, Middle East & Africa, heterogeneity in healthcare systems produces a wide range of access and delivery models. Some European countries have well-established national pathways and funding mechanisms for specialized eating-disorder services, whereas other jurisdictions contend with limited specialist capacity and stigma-related barriers to care. In parts of the Middle East and Africa, community outreach and task-shared models are gaining traction to address shortages in specialist clinicians, and partnerships between public and private providers are emerging to expand access.

In the Asia-Pacific region, growing clinical recognition and investment in mental health services are expanding the landscape of care, yet cultural factors and resource constraints shape help-seeking behaviors and service design. Telehealth and digital education initiatives are accelerating uptake, while localized adaptations of evidence-based therapies aim to improve acceptability and adherence. Across all regions, cross-border collaboration in research, training, and guideline development offers opportunities to disseminate best practices and reduce fragmentation in service delivery.

Assessing the organizational landscape where integrated systems, specialized clinics, telehealth platforms, and clinical developers converge to deliver multidisciplinary care

The ecosystem of organizations active in anorexia nervosa care spans integrated health systems, specialized behavioral health clinics, telehealth platforms, and pharmaceutical and device developers that supply adjunctive tools for monitoring and symptom management. Health systems and hospitals serve as hubs for medical stabilization and complex comorbidity management, often partnering with specialized clinics to ensure continuity of psychosocial care. Specialized clinics concentrate expertise in multidisciplinary care teams, including dietitians, psychologists, psychiatrists, and nurse practitioners, and they often develop programmatic pathways that can be replicated across service lines.

Telehealth providers have scaled models for virtual therapy, caregiver coaching, and stepped-care follow-up, reducing geographic barriers to specialist consultation and enabling more frequent touchpoints that support adherence. Meanwhile, pharmaceutical companies and clinical-stage developers continue to explore pharmacologic approaches for symptom management and comorbidities, recognizing that medication remains adjunctive to core psychosocial and nutritional interventions. Device and digital health vendors are introducing remote monitoring tools and adherence supports that facilitate earlier clinical intervention and more granular outcome tracking.

From an operational perspective, collaboration across these organization types is critical: integrated pathways between hospitals, specialized clinics, and telehealth platforms reduce fragmentation; partnerships with technology vendors enhance monitoring capabilities; and strategic alignment with clinical researchers accelerates the translation of evidence into practice. Stakeholders that cultivate these collaborative linkages position themselves to deliver more coordinated, patient-centered care.

Actionable strategic priorities for healthcare executives to scale capacity, integrate telehealth, fortify procurement, and embed outcome-driven clinical governance

Leaders seeking to strengthen anorexia nervosa services should prioritize actions that scale clinical capacity while safeguarding quality and continuity. First, invest in workforce development that emphasizes competency-based training for multidisciplinary teams, including physicians, dietitians, mental health clinicians, and care coordinators, and embed standardized handoff protocols across levels of care to reduce risk during transitions. Second, integrate telehealth strategically to extend specialty reach and enable stepped-care models, combining high-intensity in-person programs with virtual follow-up and caregiver coaching to sustain gains and reduce readmissions.

Third, develop robust supply-chain and procurement strategies that anticipate cost volatility and ensure uninterrupted access to essential nutritional products and monitoring equipment. Fourth, strengthen measurement systems that track clinical outcomes, functional recovery, and patient experience, and use these metrics to inform continuous improvement and payer negotiations. Fifth, foster cross-sector partnerships with academic centers and clinical researchers to participate in trials and translational studies that expand treatment options and refine best practices.

Finally, prioritize equity and cultural competence in program design by adapting therapies and outreach approaches to meet the needs of diverse populations and reduce stigma-related barriers. By advancing these priorities in parallel-workforce, telehealth integration, procurement resilience, measurement, research partnerships, and equity-organizations can build sustainable programs that deliver measurable clinical benefit and improve long-term recovery trajectories.

A transparent multi-source methodology combining literature synthesis, expert interviews, and operational data to derive clinically grounded and implementable insights

This research synthesis combines systematic literature review, expert interviews, and cross-disciplinary evidence appraisal to ensure a comprehensive and clinically grounded perspective. Peer-reviewed clinical trials, practice guidelines, and consensus statements provided the clinical scaffold for therapy and treatment recommendations, while qualitative interviews with clinicians, program directors, and payers furnished operational context and insights into barriers to access and reimbursement dynamics. Data from service providers and technology vendors informed considerations of care delivery innovation, particularly the role of telehealth and remote monitoring.

Analytic rigor was maintained through triangulation of sources and iterative validation with subject-matter experts, including clinicians experienced in adolescent and adult eating-disorder care, dietitians, and clinical operations leaders. Where primary evidence was limited-such as in novel digital interventions or emerging procurement impacts-interpretation emphasized pragmatic implications rather than definitive claims, and uncertainty was explicitly noted. Ethical and methodological standards guided the inclusion of studies, with attention to study quality, sample characteristics, and generalizability to routine clinical settings.

The synthesis deliberately avoided speculative financial estimations and instead prioritized clinically meaningful patterns, operational levers, and regional considerations to support strategic decision-making by providers, payers, and commercial partners.

Synthesis of clinical and operational priorities that reinforce integrated, developmentally informed, and resilient approaches to delivering high-quality anorexia nervosa care

Anorexia nervosa care is at an inflection point where clinical advances, delivery-model innovation, and policy shifts create opportunities to improve outcomes but also demand strategic responses from organizations across the care continuum. The imperative is clear: prioritize early and family-inclusive interventions, integrate medical and psychosocial care, and leverage telehealth and digital monitoring to augment access and continuity. Concurrently, operational resilience-particularly in procurement and supply-chain planning-remains essential to prevent service interruptions that can undermine recovery.

Stakeholders that invest in workforce competencies, standardized care pathways, and cross-sector partnerships will be better positioned to translate evidence into routine practice and to meet diverse patient needs across developmental stages. Regional differences remain salient, and the most effective programs will adapt global best practices to local cultural, regulatory, and resource realities. Ultimately, progress will depend on aligning clinical excellence with sustainable operations and payer engagement so that high-quality, accessible care becomes the norm rather than the exception.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Emergence of AI-enabled digital screening tools for early anorexia nervosa detection
  • 5.2. Expansion of telehealth platforms offering remote eating disorder therapy and support
  • 5.3. Integration of personalized nutritional supplements based on genetic and gut microbiome analysis
  • 5.4. Rising adoption of virtual reality exposure therapy to address body image distortions in patients
  • 5.5. Increased investment in mobile mental health apps with cognitive behavioral therapy modules for anorexia
  • 5.6. Growth of collaboration between insurance providers and specialist clinics to improve treatment access
  • 5.7. Development of peer-led online recovery communities leveraging social media for patient engagement

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Anorexia Nervosa Market, by Treatment Type

  • 8.1. Day Treatment Program
  • 8.2. Inpatient Hospitalization
  • 8.3. Residential Treatment

9. Anorexia Nervosa Market, by Therapy Type

  • 9.1. Nutritional Counseling
  • 9.2. Pharmacotherapy
    • 9.2.1. Atypical Antipsychotics
    • 9.2.2. Selective Serotonin Reuptake Inhibitors
  • 9.3. Psychotherapy
    • 9.3.1. Cognitive Behavioral Therapy
    • 9.3.2. Family Based Therapy
    • 9.3.3. Interpersonal Therapy

10. Anorexia Nervosa Market, by End User

  • 10.1. Hospitals
  • 10.2. Specialized Clinics
  • 10.3. Telehealth Providers

11. Anorexia Nervosa Market, by Age Group

  • 11.1. Adolescents
  • 11.2. Adults
  • 11.3. Children

12. Anorexia Nervosa Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Anorexia Nervosa Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Anorexia Nervosa Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Acadia Healthcare Company, Inc.
    • 15.3.2. Universal Health Services, Inc.
    • 15.3.3. Rogers Behavioral Health
    • 15.3.4. Eating Recovery Center, LLC
    • 15.3.5. Monte Nido & Affiliates, LLC
    • 15.3.6. Walden Behavioral Care, Inc.
    • 15.3.7. The Renfrew Center, Inc.
    • 15.3.8. Priory Group Ltd

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANOREXIA NERVOSA MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. ANOREXIA NERVOSA MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. ANOREXIA NERVOSA MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ANOREXIA NERVOSA MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ANOREXIA NERVOSA MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ANOREXIA NERVOSA MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY DAY TREATMENT PROGRAM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY DAY TREATMENT PROGRAM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY DAY TREATMENT PROGRAM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY DAY TREATMENT PROGRAM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY DAY TREATMENT PROGRAM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY DAY TREATMENT PROGRAM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY INPATIENT HOSPITALIZATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY INPATIENT HOSPITALIZATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY INPATIENT HOSPITALIZATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY INPATIENT HOSPITALIZATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY INPATIENT HOSPITALIZATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY INPATIENT HOSPITALIZATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY RESIDENTIAL TREATMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY RESIDENTIAL TREATMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY RESIDENTIAL TREATMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY RESIDENTIAL TREATMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY RESIDENTIAL TREATMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY RESIDENTIAL TREATMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY NUTRITIONAL COUNSELING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY NUTRITIONAL COUNSELING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY NUTRITIONAL COUNSELING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY NUTRITIONAL COUNSELING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY NUTRITIONAL COUNSELING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY NUTRITIONAL COUNSELING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY ATYPICAL ANTIPSYCHOTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY ATYPICAL ANTIPSYCHOTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY ATYPICAL ANTIPSYCHOTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY ATYPICAL ANTIPSYCHOTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY ATYPICAL ANTIPSYCHOTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY ATYPICAL ANTIPSYCHOTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY FAMILY BASED THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY FAMILY BASED THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY FAMILY BASED THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY FAMILY BASED THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY FAMILY BASED THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY FAMILY BASED THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY INTERPERSONAL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY INTERPERSONAL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY INTERPERSONAL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY INTERPERSONAL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY INTERPERSONAL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY INTERPERSONAL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY SPECIALIZED CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY SPECIALIZED CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY SPECIALIZED CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY SPECIALIZED CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY SPECIALIZED CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY SPECIALIZED CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY TELEHEALTH PROVIDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY TELEHEALTH PROVIDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY TELEHEALTH PROVIDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY TELEHEALTH PROVIDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY TELEHEALTH PROVIDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY TELEHEALTH PROVIDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY ADOLESCENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY ADOLESCENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY ADOLESCENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY ADOLESCENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY ADOLESCENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY ADOLESCENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY ADULTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY ADULTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY ADULTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY ADULTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY ADULTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY CHILDREN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY CHILDREN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY CHILDREN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY CHILDREN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY CHILDREN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY CHILDREN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 122. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 123. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 124. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 125. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 126. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 127. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 128. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 129. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 130. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 131. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 132. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 133. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. NORTH AMERICA ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 138. NORTH AMERICA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 140. NORTH AMERICA ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 142. NORTH AMERICA ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 144. NORTH AMERICA ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 146. NORTH AMERICA ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. NORTH AMERICA ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. LATIN AMERICA ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 152. LATIN AMERICA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 154. LATIN AMERICA ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 156. LATIN AMERICA ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 158. LATIN AMERICA ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 160. LATIN AMERICA ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. LATIN AMERICA ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. EUROPE ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. EUROPE ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. EUROPE ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 180. EUROPE ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 181. EUROPE ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 182. EUROPE ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 183. EUROPE ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 184. EUROPE ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 185. EUROPE ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 186. EUROPE ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 187. EUROPE ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 188. EUROPE ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 189. EUROPE ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. EUROPE ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. MIDDLE EAST ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 194. MIDDLE EAST ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 196. MIDDLE EAST ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 198. MIDDLE EAST ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 200. MIDDLE EAST ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 202. MIDDLE EAST ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. MIDDLE EAST ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. AFRICA ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. AFRICA ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. AFRICA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 208. AFRICA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 209. AFRICA ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 210. AFRICA ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 211. AFRICA ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 212. AFRICA ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 213. AFRICA ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 214. AFRICA ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 215. AFRICA ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 216. AFRICA ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 217. AFRICA ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. AFRICA ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 222. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 223. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 225. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 226. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 227. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 228. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 229. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 230. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 231. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. ASEAN ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. ASEAN ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. ASEAN ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 238. ASEAN ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 239. ASEAN ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 240. ASEAN ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 241. ASEAN ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 242. ASEAN ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 243. ASEAN ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 244. ASEAN ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 245. ASEAN ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 246. ASEAN ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 247. ASEAN ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 248. ASEAN ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 249. GCC ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. GCC ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. GCC ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 252. GCC ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 253. GCC ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. GCC ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 255. GCC ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 256. GCC ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 257. GCC ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 258. GCC ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 259. GCC ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 260. GCC ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 261. GCC ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 262. GCC ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPEAN UNION ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPEAN UNION ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPEAN UNION ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPEAN UNION ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPEAN UNION ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPEAN UNION ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPEAN UNION ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPEAN UNION ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPEAN UNION ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPEAN UNION ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPEAN UNION ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPEAN UNION ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPEAN UNION ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPEAN UNION ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 277. BRICS ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. BRICS ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. BRICS ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. BRICS ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. BRICS ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 282. BRICS ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 283. BRICS ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 284. BRICS ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 285. BRICS ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 286. BRICS ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 287. BRICS ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 288. BRICS ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 289. BRICS ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 290. BRICS ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 291. G7 ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 292. G7 ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 293. G7 ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 294. G7 ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 295. G7 ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 296. G7 ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 297. G7 ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 298. G7 ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 299. G7 ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 300. G7 ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 301. G7 ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 302. G7 ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 303. G7 ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 304. G7 ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 305. NATO ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 306. NATO ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 307. NATO ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 308. NATO ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 309. NATO ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 310. NATO ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 311. NATO ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 312. NATO ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 313. NATO ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 314. NATO ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 315. NATO ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 316. NATO ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 317. NATO ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 318. NATO ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 319. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 320. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 321. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 322. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 323. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 324. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 325. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 326. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 327. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 328. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 329. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 330. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 331. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 332. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 333. CANADA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 334. CANADA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 335. CANADA ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 336. CANADA ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 337. CANADA ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 338. CANADA ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 339. CANADA ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 340. CANADA ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 341. CANADA ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 342. CANADA ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 343. CANADA ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 344. CANADA ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)

TAB